|
Possible Link Between Semaglutide and Vision Loss Raises Questions
|
Written by: J. Smith |
Hits: 835
|
|
Dexcom Launches First Generative AI Platform in Glucose Biosensing
|
Written by: J. Smith |
Hits: 625
|
|
Eli Lilly and Novo Nordisk Ramp Up GLP-1 Manufacturing Capacity
|
Written by: J. Smith |
Hits: 1386
|
|
Novo Nordisk to Slash US Insulin Prices in 2026
|
Written by: J. Smith |
Hits: 1360
|
|
Eli Lilly’s Zepbound Outperforms Novo Nordisk’s Wegovy in Head-to-Head Weight Loss Study
|
Written by: J. Smith |
Hits: 753
|
|
Exploring CGM Data
|
Written by: J. Smith |
Hits: 639
|
|
Dexcom and Oura: A Strategic Partnership to Revolutionize Metabolic Health Tracking
|
Written by: J. Smith |
Hits: 885
|
|
Lilly's Three-Year SURMOUNT-1 Data Demonstrates Tirzepatide’s Role in Diabetes Prevention
|
Written by: J. Smith |
Hits: 725
|
|
Novo Nordisk Advances Semaglutide in MASH Treatment Following ESSENCE Trial Success
|
Written by: J. Smith |
Hits: 865
|
|
Wegovy’s Lowest Dose Now Available in the U.S.
|
Written by: J. Smith |
Hits: 733
|
